We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cytokeratin and CD56 aberrant co‐expression in diffuse large B‐cell lymphoma, NOS misinterpreted as metastatic neuroendocrine carcinoma by FNAC.
- Authors
Prevodnik, Veronika Kloboves; Gašljević, Gorana
- Abstract
Cytokeratin and CD56 aberrant co-expression in diffuse large B-cell lymphoma, NOS misinterpreted as metastatic neuroendocrine carcinoma by FNAC DISCUSSION Aberrant expression of cytokeratins or CD56 is an infrequent phenomenon in lymphomas.[[4]] Moreover, co-expression of cytokeratin and CD56 is exceptionally rare and has, until now, been described in only 6 out of 11 cases of plasmablastic lymphomas[6] but not in the other mature B-cell lymphomas. Cytokeratin and CD56 co-expression, uncommon tumour cell morphology, low cellularity of the FNAC sample, as well as poor quality of some of the ICC staining, resulted in misdiagnosing DLBCL, NOS as metastatic neuroendocrine carcinoma.
- Subjects
DIFFUSE large B-cell lymphomas; NEUROENDOCRINE tumors; B cells; KERATIN; RITUXIMAB; INTERMEDIATE filament proteins; KERATINOCYTE differentiation; ANAPLASTIC large-cell lymphoma
- Publication
Cytopathology, 2023, Vol 34, Issue 2, p165
- ISSN
0956-5507
- Publication type
Case Study
- DOI
10.1111/cyt.13190